

## Tremelimumab ELISA Kit

Catalogue No.: abx395085

Tremelimumab ELISA Kit is a quantitative ELISA kit for detection of Tremelimumab.

Tremelimumab (CP-675,206; previously, ticilimumab) is a fully human IgG2 monoclonal antibody and has a half-life of 22 days, which was generated in a XenoMouse murine system, that has a subnanomolar affinity for binding to human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) for treatment of patients with advanced cancers. Treatment with an anti-CTLA4 mAb prevents normal downregulation of T cells and prolongs T cell activation, thereby enhancing immune function. Generated at Abgenix (Fremont, CA) using xenomice by Pfizer, Inc. (New York), tremelimumab has been undergoing human trials for the treatment of malignant melanoma. Additionally, tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Carcinoma, and HepatoCellular Carcinoma and it has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. Recently, it has been announced by AstraZeneca and MedImmune that tremelimumab as monotherapy does not improve survival and the primary end point is not reached (D4880C00003; NCT01843374). Further data regarding DETERMINE was presented at ASCO 2016, detailing that 571 patients were enrolled and that 81% had died throughout the duration of the study. There was no statistically significant difference between treated patients and placebo patients, and side effects such as diarrhoea, loss of appetite and development of rashes were seen at higher rates in treated patients than in placebo treatments. This indicates a need for further research into the use of tremelimumab as a monotherapy as well as use in combination therapy to potentially achieve better clinical outcomes.

**Target:** Tremelimumab

**Research Area:** Biosimilars

**Reactivity:** Human

**Tested Applications:** ELISA

**Recommended dilutions:** Optimal dilutions/concentrations should be determined by the end user.

**Storage:** Shipped at 4°C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

**Validity:** The validity for this kit is 6 months.

**Stability:** The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.

**Test Range:** 234.38 ng/ml - 15000 ng/ml

**Sensitivity:** < 48.9 ng/ml

**Standard Form:** Lyophilized

**Detection Method:** Colorimetric

# Datasheet

Version: 3.0.0

Revision date: 06 Sep 2025



**Assay Type:** Competitive

**Assay Data:** Quantitative

**Sample Type:** Serum and plasma.

**CAS Number:** 745013-59-6

**Note:** THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES.

The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

For Reference Only